Kardigan Inc. burst onto the New York Stock Exchange, its shares climbing 27% in the opening session. The heart‑health biotech secured $400 million in its initial public offering, pricing the float at the top of its targeted range. The sharp rally signaled strong demand for specialty biotech equities amid a crowded IPO market, analysts note the pricing reflects confidence in its upcoming data.

Investors appear drawn to Kardigan’s pipeline of cardiovascular therapies, a segment that has benefited from recent regulatory approvals and aging demographics. The $400 million proceeds give the company runway to fund late‑stage trials and expand manufacturing capacity. Supports partnerships with major pharma groups. By locking in capital now, the firm sidesteps the dilution risk that has plagued peers relying on successive financing rounds.

The strong debut adds a sizable new player to the cardiology market, where investors have chased high‑margin drug candidates. With a robust cash position, Kardigan can accelerate its go‑to‑market strategy and potentially command premium pricing for breakthrough products. The immediate market reaction confirms that capital markets still reward focused biotech offerings with clear clinical pathways. The cash cushion also mitigates short‑term market volatility.